Cited by 259Cardiac Health and Mental HealthPhysical Activity and HealthTreatment of Major Depression

Exercise and Pharmacological Treatment of Depressive Symptoms in Patients With Coronary Heart Disease

Open access
Blumenthal, James A., Sherwood, Andrew, Babyak, Michael A., Watkins, Lana L., Smith, Patrick J., Hoffman, Benson M., O'Hayer, C. Virginia F., Mabe, Stephanie +5 more·2012·Journal of the American College of Cardiology

Abstract

Objectives The aim of this study was to assess the efficacy of exercise and antidepressant medication in reducing depressive symptoms and improving cardiovascular biomarkers in depressed patients with coronary heart disease. Background Although there is good evidence that clinical depression is associated with poor prognosis, optimal therapeutic strategies are currently not well defined. Methods One hundred one outpatients with coronary heart disease and elevated depressive symptoms underwent assessment of depression, including a psychiatric interview and the Hamilton Rating Scale for Depression. Participants were randomized to 4 months of aerobic exercise (3 times/week), sertraline (50-200 mg/day), or placebo. Additional assessments of cardiovascular biomarkers included measures of heart rate variability, endothelial function, baroreflex sensitivity, inflammation, and platelet function. Results After 16 weeks, all groups showed improvement on Hamilton Rating Scale for Depression scores. Participants in both the aerobic exercise (mean -7.5; 95% confidence interval: -9.8 to -5.0) and sertraline (mean -6.1; 95% confidence interval: -8.4 to -3.9) groups achieved larger reductions in depressive symptoms compared with those receiving placebo (mean -4.5; 95% confidence interval: -7.6 to -1.5; p = 0.034); exercise and sertraline were equally effective at reducing depressive symptoms (p = 0.607). Exercise and medication tended to result in greater improvements in heart rate variability compared with placebo (p = 0.052); exercise tended to result in greater improvements in heart rate variability compared with sertraline (p = 0.093). Conclusions Both exercise and sertraline resulted in greater reductions in depressive symptoms compared to placebo in patients with coronary heart disease. Evidence that active treatments may also improve cardiovascular biomarkers suggests that they may have a beneficial effect on clinical outcomes as well as on quality of life. (Exercise to Treat Depression in Individuals With Coronary Heart Disease; NCT00302068).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2012.04.040

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Other controlled trials have demonstrated modest improvements associated with SSRIs in patients with heart disease on surrogate markers, including heart rate variability and mental stress-induced myocardial ischemia, although other studies have found no such effect on clinical events or other markers.

    “Other controlled trials have demonstrated modest improvements associated with SSRIs in patients with heart disease on surrogate markers, including heart rate variability 179 and mental stress-induced myocardial ischemia, 180 although other studies have found no such effect on clinical events or other markers. 179,181”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 4

  1. [4]Lichtman JH Bigger JT Jr. Blumenthal JA AHA science advisory Depression and coronary heart disease. Recommendations for screening, referral, and treatment. Circulation 2008 118 1768 1775 18824640
  2. [5]Thombs BD Bass EB Ford DE Prevalence of depression in survivors of acute myocardial infarction J Gen Intern Med 2006 21 30 8 16423120 PMC1484630
  3. [26]Kop WJ Gottdiener JS Tangen CM Inflammation and coagulation factors in persons > 65 years of age with symptoms of depression but without evidence of myocardial ischemia Am J Cardiol 2002 89 419 424 11835923
  4. [30]Williams JB A structured interview guide for the Hamilton Depression Rating Scale Arch Gen Psychiatry 1988 45 742 7 3395203

Cited by

Sorted by citations

Authors
Blumenthal, J. A., Sherwood, A., Babyak, M. A., Watkins, L. L., Smith, P. J., Hoffman, B. M., O'Hayer, C. V. F., Mabe, S., Johnson, J., Doraiswamy, P. M., Jiang, W., Schocken, D. D., & Hinderliter, A. L.
Affiliations
  • Duke University (US)
  • Duke Medical Center (US)
  • University of North Carolina at Chapel Hill (US)
Corresponding author
Blumenthal, James A.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2012-09
Volume
60
Issue
12
Pages
1053-1063
ISSN
0735-1097 (ISSN-L)
OpenAlex
W22938527
Cited by
259
References
53
Citations by year
2026: 12 · 2025: 17 · 2024: 18 · 2023: 15 · 2022: 14 · 2021: 17 · 2020: 16 · 2019: 13 · 2018: 18 · 2017: 17 · 2016: 25 · 2015: 20 · 2014: 28 · 2013: 23 · 2012: 5
FWCI
15.64
Type
journal article
Language
en
Open access
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Heart, Lung, and Blood Institute, National Institutes of Health (HL080664)
  • General Clinical Research Center program, National Center for Research Resources, National Institutes of Health (M01-RR-30)
  • Pfizer Pharmaceuticals, Inc.
  • Bristol-Myers Squibb
  • Pfizer
  • Shire
  • Lundbeck
  • AstraZeneca
  • Otsuka
  • Clarimedix
  • Sonexa
  • Baxter
  • Lilly
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
  • Health Sciences › Medicine › Physiology › Physical Activity and Health
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Keywords
depression, coronary artery disease, aerobic exercise, sertraline, antidepressants, depressive symptoms, heart rate variability, endothelial function, baroreflex sensitivity, inflammation, platelet function, cardiovascular biomarkers, exercise therapy
MeSH terms
Aged, Antidepressive Agents, Coronary Disease, Depression, Exercise Therapy, Humans, Male, Middle Aged, Prognosis, Exercise, Treatment Outcome, Sertraline, Comprehension

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review